Salivary cortisol during opiate dependence and withdrawal

Addiction Biology

Volumn 6, Issue 2, 2001, Pages 157-162

  Bearn, J ^a,b   Buntwal, N ^a   Papadopoulos, A ^a   Checkley, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BETHLEM ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; LOFEXIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; WITHDRAWAL SYNDROME;

EID: 0035024024     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210020040235     Document Type: Article

References (24)

1. 1. Ziz AP, Haskett RF, Albala AA, Carroll BJ. Morphine inhibits Cortisol and stimulates prolactin secretion in man. Psychoneuroendocrin 1984;9: 423-7.
2. 2. Pickard D, Davis GC, Schultz SC, et al. Behavioural and biological effects of acute β-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry 1981;138:160-6.
3. 3. Facchinetti F, Volpe A, Farci G,, et al. Hypothalamo-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend 1985;50:361-6.
4. 4. Morley JE, Baranetsky NG, Winger TV, et al. Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrin Metab 1980;50:251-7.
5. 5. Pheterson A, Dackis CA, Gold MS, Sweeney DR. Plasma cortisol levels in opiate addicts before and after detoxification. Proc Soc Neurosc 1983 (abstr. 123-11): 417.
6. 6. Cami J, Gilabert M, San L, De La Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br J Addict 1992;87:145-51.
7. 7. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998;51:23-47.
8. 8. Wolff K, Farrell M, Marsden J, et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 1999;94:1279-98.
9. 9. Kirschbaum C, Hellhammer D. Methodological aspects of salivary cortisol measurement. In: Kirschbaum C, Read GF, Hellhammer D, editors. Assessment of hormones and drugs in saliva in biobehavioural research. Seattle: Hogrefe and Huber; 1992, pp. 19-31.
10. 10. Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 1998;50:227-32.
11. 11. Gossop M. The development of a short opiate withdrawal scale (SOWS). Addict Behav 1990;15: 487-90.
12. 12. Barnard G, Papadopoulos A, Checkley SA. Development of a time resolved fluoroimmunoassay (TR-FIA) for the measurement of cortisol in saliva. Unpublished.
13. 13. Kirschbaum C, Strasburger CV, Jammers W, Hellhammer DH. Cortisol and behaviour: adaptation of a radioimmunoassay kit for reliable and inexpensive salivary cortisol determination. Pharmacol Biochem Behaviour 1989;34:747-51.
14. 14. Kennedy JA, Hartman N, Sbriglio R, Khuri E, Kreek MJ. Metyrapone-induced withdrawal symptoms. Br J Addict 1990;85:1133-40.
15. 15. Heinricks SC, Menzaghi F, Schulteis G, Koob GF, Stinus L. Supression of corticotrophin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 1995;6:74-80.
16. 16. Kreek MJ. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. J Neurochem Res 1996;21:1469-88.
17. 17. Kreek MJ, Wardlaw SL, Hartman N, et al. Circadian rhythms and levels of beta-endorphin, ACTH and cortisol during chronic methadone maintenance treatment in humans. Life Sci 1983; 33(suppl.):409-11.
18. 18. Siever LJ, Uhde TW. New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha-2 adrenergic agonist clonidine. Biol Psychiatry 1984;19:131-56.
19. 19. Rosen MI, McMahon TJ, Hameedi FA, et al. Effects of clonidine pre-treatment on naloxone-precipitated opiate withdrawal. J Pharm Exp Ther 1996;276:1128-35.
20. 20. Martin WR, Jasinski DR. Physiological parameters of morphine dependence in tolerance, early abstinence and protracted abstinence. J Psychiatr Res 1969;7:9-17.
21. 21. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe JH, editors. Addictive states. New York: Raven Press; 1992, pp. 205-30.
22. 22. Piazza PV, Le Moal M. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids and dopaminergic neurons. Ann Rev Pharmacol Toxicol 1996; 6:359-78.
23. 23. Piazza PV, Maccari S, Deminière JM, Le Moal M, Mormede P, Simon H. Corticosterone levels determine individual vulnerability to amphetamines self-administration Proc Natl Acad Sci USA 1991;88:2088-92.
24. 24. Marinelli M, Piazza PV, Deroche V, Maccari S, Le Moal M, Simon H. Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effects of cocaine and morphine. J Neurosci 1994;14:2724-31.